The following articles (labelled with PubMed ID or TBD) are for your review
PMID | Data | Article Title | Organization |
27847272 |
131 |
3D-QSAR studies of 3-(3,4-dihydroisoquinolin-2(1H)-ylsulfonyl)benzoic acids as AKR1C3 inhibitors: Highlight the importance of molecular docking in conformation generation. |
Guangzhou Medical University |
26372652 |
21 |
Pentafluorosulfanyl-containing flufenamic acid analogs: Syntheses, properties and biological activities. |
Rwth Aachen University |
25182963 |
40 |
Synthesis of non-prenyl analogues of baccharin as selective and potent inhibitors for aldo-keto reductase 1C3. |
Gifu Pharmaceutical University |
24411201 |
150 |
Morpholylureas are a new class of potent and selective inhibitors of the type 5 17-ß-hydroxysteroid dehydrogenase (AKR1C3). |
University of Auckland |
23845281 |
25 |
Discovery of 2-methyl-1-{1-[(5-methyl-1H-indol-2-yl)carbonyl]piperidin-4-yl}propan-2-ol: a novel, potent and selective type 5 17ß-hydroxysteroid dehydrogenase inhibitor. |
Astellas Pharma |
23454516 |
92 |
Synthesis and structure-activity relationships for 1-(4-(piperidin-1-ylsulfonyl)phenyl)pyrrolidin-2-ones as novel non-carboxylate inhibitors of the aldo-keto reductase enzyme AKR1C3. |
University of Auckland |
23353746 |
46 |
2,3-diarylpropenoic acids as selective non-steroidal inhibitors of type-5 17ß-hydroxysteroid dehydrogenase (AKR1C3). |
University of Ljubljana |
23432095 |
160 |
Development of potent and selective indomethacin analogues for the inhibition of AKR1C3 (Type 5 17ß-hydroxysteroid dehydrogenase/prostaglandin F synthase) in castrate-resistant prostate cancer. |
Vanderbilt University School of Medicine |
22881866 |
57 |
Selective inhibitors of aldo-keto reductases AKR1C1 and AKR1C3 discovered by virtual screening of a fragment library. |
University of Ljubljana |
22877157 |
356 |
3-(3,4-Dihydroisoquinolin-2(1H)-ylsulfonyl)benzoic Acids: highly potent and selective inhibitors of the type 5 17-ß-hydroxysteroid dehydrogenase AKR1C3. |
University of Auckland |
22897946 |
34 |
N-Benzoyl anthranilic acid derivatives as selective inhibitors of aldo-keto reductase AKR1C3. |
University of Ljubljana |
22263837 |
262 |
Development of potent and selective inhibitors of aldo-keto reductase 1C3 (type 5 17ß-hydroxysteroid dehydrogenase) based on N-phenyl-aminobenzoates and their structure-activity relationships. |
University of Pennsylvania |
22506594 |
20 |
Selective inhibition of human type-5 17ß-hydroxysteroid dehydrogenase (AKR1C3) by baccharin, a component of Brazilian propolis. |
Gifu Pharmaceutical University |
22507964 |
17 |
Crystal structures of AKR1C3 containing an N-(aryl)amino-benzoate inhibitor and a bifunctional AKR1C3 inhibitor and androgen receptor antagonist. Therapeutic leads for castrate resistant prostate cancer. |
Perelman School of Medicine University of Pennsylvania |
16183274 |
9 |
Nonsteroidal anti-inflammatory drugs and their analogues as inhibitors of aldo-keto reductase AKR1C3: new lead compounds for the development of anticancer agents. |
University of Ljubljana |
21295979 |
91 |
Trisubstituted ureas as potent and selective mPGES-1 inhibitors. |
Merck Frosst Center For Therapeutic Research |
21277203 |
24 |
Discovery of substituted 3-(phenylamino)benzoic acids as potent and selective inhibitors of type 5 17ß-hydroxysteroid dehydrogenase (AKR1C3). |
University of Pennsylvania |
19237229 |
12 |
New cyclopentane derivatives as inhibitors of steroid metabolizing enzymes AKR1C1 and AKR1C3. |
University of Ljubljana |
19397269 |
16 |
Structure-guided design, synthesis, and evaluation of salicylic acid-based inhibitors targeting a selectivity pocket in the active site of human 20alpha-hydroxysteroid dehydrogenase (AKR1C1). |
Monash University (Parkville Campus) |
18472187 |
12 |
Steroidal lactones as inhibitors of 17beta-hydroxysteroid dehydrogenase type 5: chemical synthesis, enzyme inhibitory activity, and assessment of estrogenic and androgenic activities. |
Chul Research Center and University Laval |
32847363 |
66 |
Development of Novel AKR1C3 Inhibitors as New Potential Treatment for Castration-Resistant Prostate Cancer. |
Gifu Pharmaceutical University |
27563402 |
24 |
Selective AKR1C3 Inhibitors Potentiate Chemotherapeutic Activity in Multiple Acute Myeloid Leukemia (AML) Cell Lines. |
Texas Tech University Health Sciences Center |
27486833 |
37 |
Discovery of (R)-2-(6-Methoxynaphthalen-2-yl)butanoic Acid as a Potent and Selective Aldo-keto Reductase 1C3 Inhibitor. |
University of Pennsylvania |
30996776 |
12 |
Bioisosteres of Indomethacin as Inhibitors of Aldo-Keto Reductase 1C3. |
University of Turin |
30836001 |
133 |
Potent and Highly Selective Aldo-Keto Reductase 1C3 (AKR1C3) Inhibitors Act as Chemotherapeutic Potentiators in Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia. |
Texas Tech University Health Sciences Center |
30429100 |
59 |
Screening, synthesis, crystal structure, and molecular basis of 6-amino-4-phenyl-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitriles as novel AKR1C3 inhibitors. |
Guangzhou Medical University |
29602039 |
32 |
Potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the benzoisoxazole moiety: application of a bioisosteric scaffold hopping approach to flufenamic acid. |
University of Torino |
28881288 |
30 |
Hydroxytriazole derivatives as potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors discovered by bioisosteric scaffold hopping approach. |
University of Torino |
28976752 |
51 |
Synthesis of Potent and Selective Inhibitors of Aldo-Keto Reductase 1B10 and Their Efficacy against Proliferation, Metastasis, and Cisplatin Resistance of Lung Cancer Cells. |
Gifu Pharmaceutical University |
6248635 |
48 |
Opioid binding properties of brain and peripheral tissues: evidence for heterogeneity in opioid ligand binding sites. |
Stanford University |
18842034 |
25 |
Potent, selective and orally bioavailable dihydropyrimidine inhibitors of Rho kinase (ROCK1) as potential therapeutic agents for cardiovascular diseases. |
Gsk |
16460937 |
6 |
Synthesis and evaluation of novel heterocyclic inhibitors of GSK-3. |
Glaxosmithkline |